Press Releases

 
Press Releases
Date Title and Summary View
Aug 21, 2014 PORTLAND, Ore., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., has been appointed as President and Chief ...
Aug 11, 2014 Abstral® (fentanyl) sublingual tablet net revenue was $2.3 million in Q2 2014 and $4.5 million in 1H 2014. U.S. license of Zuplenz® (ondansetron) oral soluble film expands portfolio to two commercial products. On track to reach two significant milestones in 2H 2014: completing enrollment activities in the NeuVax™ (nelipepi...
Jul 29, 2014 PORTLAND, Ore., July 29, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that the Company will report its second quarter financial results on Monday, August...
Jul 22, 2014 Novel, rapidly dissolving oral PharmFilm® enables faster absorption, increased convenience and better compliance for patients. Planned launch in multiple indications—chemotherapy-, radiation- and post operative-induced nausea and vomiting—in early 2015. FDA-Approved product to be added to Galena's established oncology com...
Jul 1, 2014 PORTLAND, Ore., July 1, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the notice of allowance of a U.S. Patent for NeuVax™ (nelipepimut-S) covering ...
Jun 19, 2014 PORTLAND, Ore., June 19, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark W. Schwartz, Ph.D., Executive Vice President and Chief Operating Officer ...
Jun 17, 2014 PORTLAND, Ore., June 17, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the completion of enrollment in the Company's Phase 2a clinical trial for GALE-301,...
Jun 2, 2014 Phase 1 study demonstrates GALE-301 (Folate Binding Protein) cancer immunotherapy is well tolerated and induces an immune response in ovarian and endometrial cancer patients.Ongoing Phase 2a trials to establish preliminary efficacy, as well as evaluate a longer-term booster regimen, to complete enrollment this year. PORTLAND, Ore., June 2, 2014...
May 30, 2014 PORTLAND, Ore., May 30, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Mark J. Ahn, Ph.D., President and Chief Executive Officer will present a corporate up...
May 23, 2014 PORTLAND, Ore., May 23, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced that Ryan Dunlap, Vice President and Chief Financial Officer, will present a corporate upd...
Page:
1
... NextLast
= add release to Briefcase